This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

  • Clinicaltrials.gov identifier

    NCT04392102

  • Recruitment Status

    Active, not recruiting

  • First Posted

    May 18, 2020

  • Last update posted

    May 26, 2021

Study Description

Brief summary:

This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.

  • Condition or Disease:Ovarian Cancer
  • Intervention/Treatment: Drug: ZL-2306(Niraparib)
  • Phase: Phase 2

Detailed Description

N/A

Study Design

  • Study Type: Interventional
  • Actual Enrollment: 15 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced and Relapsed Ovarian Cancer After 3 or 4 Previous Chemotherapies
  • Actual Study Start Date: August 2020
  • Estimated Primary Completion Date: April 2021
  • Actual Study Completion Date: July 2023

Arms and interventions

Arm Intervention/treatment
Experimental: ZL-2306(Niraparib)
The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Drug: ZL-2306(Niraparib)
The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count

Outcome Measures

  • Primary Outcome Measures: 1. Objective Response Rate(ORR) [ Time Frame: Up to 3 years ]
    The ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) (version1.1).
  • Secondary Outcome Measures: 1. Duration of Response (DoR) [ Time Frame: Up to 3 years ]
    DoR was defined as the time from first documentation of CR or PR until the time of first documentation of disease progression (PD) as assessed by the Investigator per RECIST (version1.1).
  • 2. Disease Control Rate (DCR) [ Time Frame: Up to 3 years ]
    Disease control rate was defined as the percentage of participants achieving CR, PR, or stable disease (SD) as assessed by the Investigator per RECIST (version1.1). The exact method was used to calculate 95% confidence interval.
  • 3. Progression Free Survival (PFS) [ Time Frame: Up to 3 years ]
    Progression-free survival was defined as the time from the date of first dose to the earlier date of assessment of progression or death by any cause in the absence of progression as assessed by the Investigator per RECIST (version 1.1).
  • 4. Overall Survival (OS) [ Time Frame: Up to 3 years ]
    Overall Survival was defined as the time from the date of the first dose to the date of death by any cause.
  • 5. Number of Participants With Any Non-serious Adverse Event (Non-SAE) or Any SAE To evaluate the safety and tolerability of niraparib [ Time Frame: Up to 3 years ]
    An adverse event is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria: - 1. Patients must be female and at least 18 years of age - 2. Patients must provide written informed consent - 3. Patients must be gBRCA mutation or HRD positive - 4. Patients must have histologically diagnosed high-grade (Grade 2 or 3)serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent disease. - 5. Patients Must have completed 3 or 4 previous chemotherapy regimens. - 6. Patients must have measurable disease according to RECIST (v.1.1). - 7. Patients must have an Eastern Cooperative Oncology Group(ECOG) performance status of 0 or1 - 8. Patients must have adequate organ function, defined as follows: a. Absolute neutrophil count≥1500/ul b. Platelets ≥150000/ul c. Hemoglobin≥10g/dL d. Serum creatinine≤1.5X upper limit of normal (ULN)or calculated creatinine clearance≥60ml/min using the Cockcroft-Gault equation e. Total bilirubin≤1.5X ULN OR direct bilirubin≤1X ULN f. Aspartate aminotransferase and alanine aminotransferase≤2.5X ULN unless liver metastases are present, in which case they must be ≤5X ULN - 9. Patients must be either postmenopausal, free from menses for>12 months, surgically sterilized, or willing to use adequate contraception to prevent pregnancy or must agree to abstain from heterosexual activity throughout the study, starting with enrollment through 90 days after the last dose of study treatment - 10. Patients must have formalin-fixed, paraffin-embedded tumor samples available form primary or recurrent cancer. - 11. Patients must be able to take oral medications and capable of complying with treatment and follow up visit Exclusion Criteria: - 1. Patients who have received other investigational drugs within 4 weeks or 5X t1/2 before first dose of study treatment. - 2. Patients have had palliative radiotherapy encompassing>20% of the bone marrow within 3 weeks of the first dose of study treatment. - 3. Patients have any known, persistent(>4 weeks),≥Grade 3 anemia, neutrophil count decrease or platelet count decrease during the last chemotherapy. - 4. Patients have any known, persistent (>4 weeks), ≥ Grade 3 fatigue during the last chemotherapy. - 5. Patients have received pelvic radiotherapy as treatment for primary or recurrent disease within 1 year of the first dose of study treatment. - 6. Patients have symptomatic uncontrolled brain or leptomeningeal metastases. The patient have new or progressive signs or symptoms related to the CNS disease and not taking a stable dose of steroids or no steroids. A scan to confirm the absence of brain metastases is not required. - 7. Patients have known hypersensitivity to the components of niraparib - 8. Patient have had major surgery within 3 weeks of fist dose treatment and patient must have recovered form any effects of any major surgery - 9. Patients have had diagnosis, detection, or treatment of invasive cancer other than ovarian cancer ≤2 years prior to enrollment(except basal or squamous cell carcinoma of the skin that has been definitively treated) - 10. Patients are considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to: 1. uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction 2. uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome or any psychiatric disorder that prohibits obtaining informed consent 3. immune deficiency (not including splenectomy) 4. HIV infection or active hepatitis(i.e. hepatitis B with HBV-DNA>500IU/ml or hepatitis C with positive HCV-RNA). - 11. Patients have received a transfusion (platelets or red blood cells) within 4 weeks of the first dose of study treatment. - 12. Patients have known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). - 13. Patients have current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with patient's participation for the full duration of the study treatment or that makes it not in the best interest of the patient to participate

Contacts and Locations

Contacts

Locations

China, Beijing
Beijing Cancer Hospital
Beijing

China, Beijing
Cancer Hospital Chinese Academy of Medical Sciences
Beijing

China, Guangdong
Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Guangzhou

China, Heilongjiang
Harbin Medical University
Haerbin

China, Shanghai
Fudan University Shanghai Cancer Center
Shanghai

China, Sichuan
West China Second Iniversity Hospital
Chengdu

China, Zhejiang
Sir Run Shaw Hospital, school of medicine, Zhejiang University
Guangzhou

Sponsors and Collaborators

Zai Lab (Shanghai) Co., Ltd.

Investigators

Principal Investigator: Rutie Yin West China Second University Hospital

Principal Investigator: Xiaohua Wu Fudan University

Principal Investigator: Hong Zheng Beijing Cancer Hospital

Principal Investigator: Ge Lou Harbin Medical University

Principal Investigator: Lingying Wu Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Principal Investigator: Hongmin Pan Sir Run Shaw Hospital, school of medicine, Zhejiang University

Principal Investigator: Zhongqiu Lin Sun Yat-sen Memorial Hospital,Sun Yat-sen University

More Information

  • Responsible Party: Zai Lab (Shanghai) Co., Ltd.
  • ClinicalTrials.gov Identifier: NCT04392102 History of Changes
  • Other Study ID Numbers: ZL-2306-008
  • First Posted: May 18, 2020 Key Record Dates
  • Last Update Posted: May 26, 2021
  • Last Verified: May 2021
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Carcinoma, Ovarian Epithelial Ovarian Neoplasms